成人脑胶质母细胞瘤：神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）关于当前管理和未来方向的共识综述。
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
机构信息
Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
出版信息
Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106.
Abstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
摘要
胶质母细胞瘤是最常见的恶性原发性脑肿瘤，也是发病率和死亡率的重要原因。近年来，人们对这些肿瘤的分子发病机制和生物学有了重要的认识，但这并没有转化为患者结局的显著改善。在这篇来自神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）的共识综述中，将讨论异柠檬酸脱氢酶野生型（IDHwt）胶质母细胞瘤的当前治疗方法。此外，还将回顾新型治疗方法，如靶向分子治疗、针对 DNA 损伤反应和代谢的药物、免疫疗法和病毒疗法，以及当前的研究挑战和未来方向。
相似文献
1
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.成人脑胶质母细胞瘤：神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）关于当前管理和未来方向的共识综述。
Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106.
2
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.异柠檬酸脱氢酶（IDH）突变型脑胶质瘤：神经肿瘤学会（SNO）关于诊断、管理和未来方向的共识综述。
Neuro Oncol. 2023 Jan 5;25(1):4-25. doi: 10.1093/neuonc/noac207.
3
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.成人胶质母细胞瘤：神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）关于当前治疗及未来方向的共识综述
Neuro Oncol. 2021 Mar 25;23(3):502-503. doi: 10.1093/neuonc/noaa287.
4
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.携带异柠檬酸脱氢酶1/2（IDH1/2）突变的胶质母细胞瘤临床病程短，临床预后良好。
Jpn J Clin Oncol. 2016 Jan;46(1):31-9. doi: 10.1093/jjco/hyv170. Epub 2015 Nov 24.
5
Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.成人低级别胶质瘤的最新进展和未来方向：神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）共识。
Neuro Oncol. 2019 Jul 11;21(7):837-853. doi: 10.1093/neuonc/noz033.
6
Updates in IDH-Wildtype Glioblastoma.IDH 野生型胶质母细胞瘤的最新进展。
Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.
7
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.异柠檬酸脱氢酶（IDH）野生型脑胶质瘤的治疗进展。
Curr Neurol Neurosci Rep. 2023 Jun;23(6):263-276. doi: 10.1007/s11910-023-01268-0. Epub 2023 May 8.
8
Management of glioblastoma: State of the art and future directions.脑胶质瘤的治疗：现状与未来方向。
CA Cancer J Clin. 2020 Jul;70(4):299-312. doi: 10.3322/caac.21613. Epub 2020 Jun 1.
9
Molecular Evolution of Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.标准治疗下的野生型胶质母细胞瘤的分子进化会影响生存和精准医学试验的设计：来自 EORTC 1542 研究的报告。
J Clin Oncol. 2020 Jan 1;38(1):81-99. doi: 10.1200/JCO.19.00367. Epub 2019 Nov 19.
10
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.异柠檬酸脱氢酶状态与胶质瘤和胶质母细胞瘤的分子亚类
Neurosurg Focus. 2014 Dec;37(6):E13. doi: 10.3171/2014.9.FOCUS14505.
引用本文的文献
1
Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.胶质母细胞瘤：从病理生理学到新型治疗方法
Biomedicines. 2025 Aug 12;13(8):1963. doi: 10.3390/biomedicines13081963.
2
The Evidence That Brain Cancers Could Be Effectively Treated with In-Home Radiofrequency Waves.脑癌可通过家用射频波有效治疗的证据。
Cancers (Basel). 2025 Aug 15;17(16):2665. doi: 10.3390/cancers17162665.
3
Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance.解读腺苷脱氨酶作用于RNA（ADARs）在癌症发病机制、肿瘤免疫逃逸和耐药性中的机制性作用。
Front Immunol. 2025 Aug 7;16:1621585. doi: 10.3389/fimmu.2025.1621585. eCollection 2025.
4
A deep learning model to predict glioma recurrence using integrated genomic and clinical data.一种利用整合的基因组和临床数据预测神经胶质瘤复发的深度学习模型。
Commun Med (Lond). 2025 Aug 19;5(1):359. doi: 10.1038/s43856-025-01083-3.
5
Membrane flexibility induced by BST2 contributes to radioresistance in glioblastoma.BST2诱导的膜柔韧性有助于胶质母细胞瘤的放射抗性。
Oncogene. 2025 Aug 18. doi: 10.1038/s41388-025-03544-4.
6
Analysis of epidemiology and nomogram construction for prediction and clinical decision-making in gliomas.胶质瘤的流行病学分析及预测与临床决策列线图构建
Front Immunol. 2025 Aug 1;16:1624142. doi: 10.3389/fimmu.2025.1624142. eCollection 2025.
7
Isovalerylspiramycin I Reprograms the Immunosuppressive and Temozolomide-Resistant Microenvironment by Inhibiting the Frizzled-5/Wnt/β-Catenin Pathway in Glioblastoma.异戊酰螺旋霉素I通过抑制胶质母细胞瘤中的卷曲蛋白-5/ Wnt/β-连环蛋白信号通路来重塑免疫抑制和耐替莫唑胺的微环境。
Research (Wash D C). 2025 Aug 13;8:0828. doi: 10.34133/research.0828. eCollection 2025.
8
Central Nervous System Tumors in Adolescents and Young Adults.青少年和青年的中枢神经系统肿瘤
Curr Neurol Neurosci Rep. 2025 Aug 12;25(1):58. doi: 10.1007/s11910-025-01440-8.
9
Postoperative Abulia Following Resection of Bilateral Anterior Cingulate Gyrus Glioblastoma: A Case Report and Lessons Learned.双侧前扣带回胶质母细胞瘤切除术后的术后意志缺失：一例报告及经验教训
Cureus. 2025 Jul 8;17(7):e87547. doi: 10.7759/cureus.87547. eCollection 2025 Jul.
10
Profiling with senescence-associated secretory phenotype score identifies GDC-0879 as a small molecule sensitizing glioblastoma to anti-PD1.通过衰老相关分泌表型评分进行分析发现，GDC-0879是一种使胶质母细胞瘤对抗PD1敏感的小分子。
Cell Death Dis. 2025 Aug 9;16(1):602. doi: 10.1038/s41419-025-07915-3.
本文引用的文献
1
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma.胶质母细胞瘤创新疗法个体化筛查试验（INSIGhT）：一项贝叶斯适应性平台试验，旨在为胶质母细胞瘤患者开发精准药物。
JCO Precis Oncol. 2019 Mar 27;3. doi: 10.1200/PO.18.00071. eCollection 2019.
2
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果：CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
3
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).一项在胶质母细胞瘤患者中进行的 6 周期以上继续辅助替莫唑胺的 II 期随机、多中心、开放标签试验（GEINO 14-01）。
Neuro Oncol. 2020 Dec 18;22(12):1851-1861. doi: 10.1093/neuonc/noaa107.
4
Mechanisms and therapeutic implications of hypermutation in gliomas.胶质母细胞瘤中突变的机制及治疗意义。
Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15.
5
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.cIMPACT-NOW更新5：IDH突变型星形细胞瘤的推荐分级标准和术语
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
6
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.优化入组标准和临床试验实施，以提高原发性脑肿瘤患者参与临床试验的比例。
Neuro Oncol. 2020 May 15;22(5):601-612. doi: 10.1093/neuonc/noaa015.
7
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.在进展性或复发性高级别神经胶质瘤患者中评估具有脑穿透性的 PI3K/mTOR 抑制剂 GDC-0084 的首次人体 I 期研究。
Clin Cancer Res. 2020 Apr 15;26(8):1820-1828. doi: 10.1158/1078-0432.CCR-19-2808. Epub 2020 Jan 14.
8
Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort.成人复发性神经胶质瘤的病理和分子特征标准化研究：神经肿瘤评估学的努力。
Neuro Oncol. 2020 Apr 15;22(4):450-456. doi: 10.1093/neuonc/noz233.
9
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).一项 VB-111 联合贝伐珠单抗对比贝伐珠单抗单药治疗复发性胶质母细胞瘤（GLOBE）的随机对照 III 期研究。
Neuro Oncol. 2020 May 15;22(5):705-717. doi: 10.1093/neuonc/noz232.
10
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.VB-111，一种抗肿瘤基因疗法，在复发性胶质母细胞瘤患者中的安全性和疗效：I/II 期研究结果。
Neuro Oncol. 2020 May 15;22(5):694-704. doi: 10.1093/neuonc/noz231.
Zotero 插件